EFTA Document EFTA01461637
Ariad (outlier due to M&A prospects vs. group drivers) 1-mo price history charts below. DescuipUon Trade Date Quantify Current Pace Unit Cost Market Value Current Total Cost Unrealized G/L SANGAMO SIOSCIENCES 5/28/2013 50,000.00 $ 17.51 S 8.44 $ 875,500.00 422.214.00 S 453,286.00 BIOGEN 2/14/2012 2,095.00 $ 308.71 $ 119.55 $ 646,747.45 250,454.95 $ 396,292.50 rancsmat MEDICINE L/13/20 la 25,000.00 $ 31.62 27.51 S 790,500.0D 667,663.50 $ 102,836.50 GILEAD SCIE
Summary
Ariad (outlier due to M&A prospects vs. group drivers) 1-mo price history charts below. DescuipUon Trade Date Quantify Current Pace Unit Cost Market Value Current Total Cost Unrealized G/L SANGAMO SIOSCIENCES 5/28/2013 50,000.00 $ 17.51 S 8.44 $ 875,500.00 422.214.00 S 453,286.00 BIOGEN 2/14/2012 2,095.00 $ 308.71 $ 119.55 $ 646,747.45 250,454.95 $ 396,292.50 rancsmat MEDICINE L/13/20 la 25,000.00 $ 31.62 27.51 S 790,500.0D 667,663.50 $ 102,836.50 GILEAD SCIE
Ask AI About This Document
Extracted Text (OCR)
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.